Resolutions at the Annual General Meeting 2017
At the Annual General Meeting of RaySearch Laboratories AB (publ) held on May 23, 2017, the following resolutions were adopted.
It was resolved that the accumulated profit, amounting to SEK 177,389,770 be brought forward and balanced in the new accounts.
The Annual General Meeting adopted the balance sheets and income statements and discharged the members of the Board and the CEO from personal liability.
It was resolved to adopt the guidelines for remuneration to senior executives proposed by the Board, to apply until the close of the Annual General Meeting 2018.
It was resolved that remuneration to Board members who do not receive a salary from any Group company, amount to a total of SEK 980,000 for the period extending to the close of the next Annual General Meeting, of which SEK 480,000 to the Chairman and SEK 250,000 to each of the Board members elected by the Annual General Meeting, who do not receive a salary from any Group company.
It was resolved that the Auditor’s fees be paid in accordance with current approved invoicing.
It was resolved to re-elect Carl Filip Bergendal, Johan Löf and Hans Wigzell as Board members of the company, to elect Johanna Öberg as new board member and to appoint Carl Filip Bergendal as Chairman of the Board.
It was resolved to re-elect the auditing firm Ernst & Young as Auditors, with the authorized public accountant Per Hedström as auditor in charge.
It was resolved to authorize the Board to resolve on new issues of Series B shares and/or issues of convertible debt instruments, on one or several occasions up until the Annual General Meeting of 2018, in accordance with the proposal by the Board.
About RaySearch
RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved radiation therapy of cancer. RaySearch develops and markets the RayStation® treatment planning system to clinics all over the world and distributes the products through licensing agreements with leading medical technology companies. The company is also developing the next-generation oncology information system, RayCare®, which comprises a new product area for RaySearch, and will be launched in 2017. RaySearch’s software is currently used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since November 2003.
For more information about RaySearch, visit www.raysearchlabs.com.
For further information, please contact:
Johan Löf, President and CEO, RaySearch Laboratories AB (publ)
Telephone: +46 (0)8-510 530 00
johan.lof@raysearchlabs.com